The high-sensitivity C-reactive protein concentration was significantly reduced in the rosiglitazone group compared with that in the control group (from 2.92 ± 1.98 to 0.62 ± 0.44 mg/l, P < 0.001 vs. from 2.01 ± 1.33 to 1.79 ± 1.22 mg/l, P = NS). However, the baseline and follow...
Other regions of the cochlea such as the spiral ligament (SL), stria vascularis (SV) and spiral ganglion nerve (SGN) fibers are also susceptible to cisplatin- induced damage.5–9 The generation of reactive oxygen species (ROS) has long been recognized as an important contributor to cisplatin-...
Cisplatin-induced ototoxicity is one of the major factors limiting cisplatin chemotherapy. Ototoxicity results from damage to outer hair cells (OHCs) and other regions of the cochlea. At the cellular level, cisplatin increases reactive oxygen species (ROS) leading to cochlear inflammation and apoptosis...
Moreover, this vaccine elicits antibodies that are not only reactive to EBOV and SUDV GPs, but also cross-reactive against BDBV GPs. The currently available vaccines may induce long-term protection, although the exact duration is unknown. As a result, these vaccines may be used in captive ...
Metabolites 2022, 12, 957 3 of 20 Although the pathophysiology of UC is still elusive, oxidative stress has been an important factor in UC progression, as the overproduction of reactive oxygen species (ROS) may cause oxidative damage to cellular biomolecules [10]. PACs contain many hydroxyl ...
VDR, vitamin D receptor; PDIA3, Protein disulfide-isomerase A3; RXR, retinoid X receptor; L-VGCC, L-type voltage-gated calcium channel; Cav1, L-type voltage-gated calcium subunit 1; TRPV1, transient receptor potential vanilloid subfamily member 1; ROS, reactive oxygen species; iNOS, inducib...
The model is both predictive and reactive, providing a personalised, risk-targeted algorithm for P-TP. This risk-score based decision-making algorithm is currently being tested in a randomised interventional study (TARGET-TP), among patients with both NSCLC and gastrointestinal cancer receiving ...